Botulinum toxin A for the treatment of cervical dystonia

Theresa A. Zesiewicz, William Stamey, Kelly L. Sullivan, Robert A. Hauser

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox®. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport®. Success rates for BTX-A injections for ICD ranges 64 - 90%, with 76 - 93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness. 2004

Original languageEnglish
Pages (from-to)2017-2024
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume5
Issue number9
DOIs
StatePublished - Sep 2004

Scopus Subject Areas

  • Pharmacology
  • Pharmacology (medical)

Keywords

  • Botox
  • Botulinum toxin A
  • Cervical dystonia
  • Dysport

Fingerprint

Dive into the research topics of 'Botulinum toxin A for the treatment of cervical dystonia'. Together they form a unique fingerprint.

Cite this